Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03037385
Title	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)
Acronym	ARROW
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Blueprint Medicines Corporation
Indications	Advanced Solid Tumor medullary thyroid carcinoma lung non-small cell carcinoma
Therapies	Pralsetinib
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL